Cabaletta Bio Inc., co-founded by Michael C. Milone, MD, PhD, Associate Professor of Pathology and Laboratory Medicine, Aimee Payne, MD, PhD, Professor of Dermatology, and Steven Nichtberger, an adjunct professor of Health Care Management, says it has raised another $50 million from investors to fund clinical trials and add manufacturing capabilities for cellular therapies that target specific B cells that mediate a wide variety of autoimmune conditions, while leaving the normal B cells alone. The new funding will help Cabaletta expand research and manufacturing in cooperation with Penn’s Center for Cellular Immunotherapies.

See article in Philadelphia Inquirer.